6				•							
Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							Complete if Known				
						-	Application Number 10/6		/685,224		
									r 14, 2003		
	(Use several sheets if necessary)]]	First Name Inventor Ding, e		t al.		
She					1	Attorney Docket Number 20861		US3			
					U.S. PA	ATE	NT DOCUMENTS	·			
		<u> </u>	U.S. Patent Document				NSP		D		
Examiner Initials'		Cite No.'	Kind Co Number (if know			de²	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document		
								MM-DD-YYYY			
		A									
						PA	TENT DOCUMENTS				
Examiner		Cite	Foreign Patent Document			}	Name of Patentee or		Date of Publication of	T	
	ials'	No.'	Office ³ Number Kind Code ⁵		Applicant of Cited Document			Cited Document	1		
				ļ.,	(if known)				MM-DD-YYYY		
	WY	B1	WO99/21845			A	Agouron Pharmaceuticals Inc.		05/06/1999		
	1	B2	WO00/75120			A	Agouron Pharmaceuticals Inc.		12/14/2000		
	\perp	B3	WO97/16447			Mitotix Inc.		05/09/1997			
		B4	WO99/43675			Hoechst Marion Roussel Inc.		09/02/1999			
	T	B5	WO99/43676 WO98/33798 WO99/09030 WO00/39101			Ho	oechst Marion Roussel	09/02/1999			
		B6				Warner Lambert Co.			08/06/1998		
		B7				Warner Lambert Co.			02/25/1999		
		B8				Astrazeneca Ltd.			07/06/2000		
		B9	WO00/12485			Zeneca Ltd.			03/09/2000		
		B10	WO9.9/24416			Bristol-Myers Squibb Co.		03/09/1999			
		B11	WO99/21845			-	gouron Pharmaceuticals	05/06/1999			
		B12	WO 00/26202			_	Pharmacia & UpJohn S.P.A.		05/11/2000		
	1	B13		1/56567			ovo Nordisk A/S		08/09/2001		
		B14	WO 01/60816				Amgen Inc.		08/23/2001		
		B15		1/79198		_	gouron Pharmaceuticals	s, Inc.	12/25/2001		
1	~/	B16	WO 02	2/12250			gouron Pharmaceuticals		02/14/2002		
<u> </u>		· · · · · · · · · · · · · · · · · · ·		NON	D 4 (DE 2)					•	
<u></u>	.//	C1	Conde				ERATURE DOCUMENT		02 mgs 276	Τ	
101	γ'	C1	Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vol. 92 pgs. 376-387								
		C2	Chong, Wesley, K. M., Presentation at Gordon Conference on								
			Medicinal Chemistry, Colby Sawyer College, New London, NH								
	1		"Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August								
			2, 1999 (Copy of Conference Handout Enclosed)								
	١ ,	C3	Fische	r et al., I	Expert O	pin.	Investig. Drugs 12(6)	pgs. 95.	5-970 (2003)		
1	4	C4	Grant et al., Drug Resista				ance Vol. 6, pgs. 15-26 (2003)				
Eva	miner		Date Co	ncidered /	1 1		(1	. 0	10 51		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this

Examiner

Signature

Date Considered

form with next communication to applicant,

'Unique citation designation number. See attached Kinds of U.S. Patent Documents, Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.